HNC280

HNC280 is a long-acting small molecule anti-HBV drug being developed by Guangzhou Henovcom Bioscience for the treatment of chronic hepatitis B virus (HBV) infection. It is formulated as a microcrystal suspension injectable designed for infrequent administration, typically once every 3 to 6 months, utilizing the company's proprietary microcrystalline technology platform for long-acting prodrugs. This long-acting approach is intended to enhance patient medication compliance and mitigate potential side effects associated with the long-term treatment of chronic hepatitis B. As of early 2025, the drug is in the pre-clinical stage, with an Investigational New Drug (IND) application anticipated in 2025.